BioSpace News Archive

Arch Biopartners Inc., announced that Anesthesia Clinical Trials Unit, an academic research organization in the Department of Anesthesia and Pain Management at the University Health Network, has joined the Phase II trial for LSALT peptide targeting the prevention and treatment of cardiac surgery-associated acute kidney injury.

Compugen Ltd. a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, announced that management will participate in the following upcoming investor conferences in April.

Carisma Therapeutics Inc., a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, announced that it will present at the following upcoming conferences.

Kintara Therapeutics, Inc. and TuHURA Biosciences, Inc. announced that they have entered into a definitive agreement for an all-stock transaction forming a company with expertise and resources to advance a risk diversified late-stage oncology pipeline.

Can-Fite BioPharma Ltd., a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, announced submission of an investigational new drug application to the U.S. Food and Drug Administration for the treatment of metabolic dysfunction-associated steatohepatitis, also known as non-alcoholic steatohepatitis, for the Company’s ongoing Phase IIb clinical study.

Glaukos Corporation announced the U.S. Centers for Medicare and Medicaid Services has assigned a unique, permanent Healthcare Common Procedure Coding System J-code for iDose® TR 75 mcg, a prostaglandin analog indicated for the reduction of intraocular pressure in patients with ocular hypertension or open-angle glaucoma.

Mereo BioPharma Group plc today announced that Dr. Denise Scots-Knight, Chief Executive Officer, will participate in a Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference on Tuesday, April 9, 2024, at 10:15am ET / 03:15pm BST.

Venus Concept Inc., a global medical aesthetic technology leader, announced that it has Therapeutic Goods Administration clearance in Australia to market the Venus Versa Pro system.

Alvotech announced today that it will host an audio call with a market update at 12:15 pm GMT / 08:15 am EDT on April 3, 2024.

Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company) announced today that it has received agreement from the European Medicines Agency (EMA) on the key design components of a confirmatory Phase 3 placebo-controlled study evaluating the safety and efficacy of HyBryte™ (synthetic hypericin) in the treatment of cutaneous T-cell lymphoma (CTCL) patients with early-stage disease.